Epitalon: Ala-Glu-Asp-Gly Pineal Tetrapeptide Research Profile

What Is Epitalon?

Epitalon is a synthetic tetrapeptide with the sequence Alanine-Glutamic acid-Aspartic acid-Glycine (H-Ala-Glu-Asp-Gly-OH), abbreviated AEDG. It is also written as Epithalon or Epithalone. Public chemistry databases list the free-base form as C₁₄H₂₂N₄O₉, with a molar mass of about 390.35 g/mol and CAS number 307297-39-8.^[1] Acetate-salt forms reported by some suppliers carry a slightly higher mass and a different elemental profile.

The compound was not discovered in isolation. It was designed from the amino-acid composition of Epithalamin, a bovine pineal-gland peptide extract studied since the 1980s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The research thesis was that a short, defined tetrapeptide could reproduce the geroprotective and neuroendocrine effects attributed to the crude pineal extract, in a form that could be synthesised and characterised.^[1]

For a research reader, the practical takeaway is that Epitalon is best understood as a geroprotection and pineal-signalling tool compound with a distinctive telomere-biology hook — not a validated longevity drug. The literature gives clear preclinical signals to study; it does not give a finished clinical product.

Where Epitalon Sits in the Pineal / Epithalamin Story

The pineal gland is the source of melatonin and a broader set of regulatory peptides, and its age-related decline has long been a candidate driver of systemic aging. Epithalamin — the crude bovine pineal extract — was the original object of study, and the reported effects (normalised circadian melatonin, improved carbohydrate and lipid metabolism, immune and cardiovascular measures) belong first to that extract.^[4]

Epitalon is the defined tetrapeptide abstraction of that work. The scientific appeal is that a four-residue peptide is trivial to synthesise, easy to characterise analytically, and — in the group's model — carried a meaningful portion of the extract's phenotype. That is the same "isolate the active fragment" logic seen elsewhere in peptide science, and it is the reason Epitalon, rather than the crude extract, is what circulates in modern research discussions.^[1]

It is worth being precise about what that does and does not mean. The tetrapeptide is biologically interesting because it is a tractable, reproducible probe of pineal geroprotection. It is not the same thing as saying Epitalon is a fully validated anti-aging therapeutic. The fragment is a research tool whose translational value remains under-tested in independent late-stage trials.

Mechanism: Melatonin, Telomerase, and Gene Signalling

A 2025 review consolidates the proposed mechanisms, and the honest summary is that Epitalon appears to act through several loosely connected pathways rather than one clean receptor:^[1]

• Melatonin and neuroendocrine signalling. Epitalon has been reported to influence melatonin synthesis and to normalise circadian patterns in aged animal models, consistent with a pineal-restorative framing.^[1]
• Telomerase / hTERT upregulation. The most-discussed mechanism is transcriptional: in cultured human cells the peptide has been reported to induce expression of the telomerase catalytic subunit (hTERT), raising telomerase activity and lengthening telomeres.^[2][3]
• Antioxidant, antimutagenic, and immune effects. Reported changes include enhanced antioxidant enzyme activity, altered interleukin-2 mRNA, and modulation of thymocyte activity — a broadly "nonspecific" geroprotective profile rather than a single defined target.^[1]

What this gives a research reader is a believable, multi-pathway mechanistic sketch rather than a one-line "Epitalon does X at receptor Y" claim. The 2025 review is explicit that the physico-chemical and structural characterisation of the peptide remains thin, so the mechanism is best treated as a live research question, not a settled model.^[1]

The Telomere Question — What the Cell Data Do and Don't Show

Two studies do most of the heavy lifting for the telomere narrative, and both are in-vitro.

1. Human fibroblast telomerase induction (Khavinson et al. 2003)

In Bulletin of Experimental Biology and Medicine, Khavinson, Bondarev, and Butyugov reported that adding Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, restored enzymatic telomerase activity, and produced telomere elongation. Control fibroblasts stopped dividing around the expected replicative limit, while treated cultures continued dividing well beyond it.^[2]

2. Dose-dependent telomere extension across cell types (2025 Biogerontology)

A 2025 Biogerontology study revisited the question quantitatively across normal epithelial/fibroblast cells and breast-cancer lines, using qPCR and immunofluorescence. It reported dose-dependent telomere-length extension in normal cells through hTERT and telomerase upregulation — the first systematic attempt to pin the biomolecular pathway rather than assert the endpoint.^[3]

The interpretation discipline matters here. Telomerase reactivation in culture is a genuine and reproducible finding, and it is mechanistically interesting. It is not evidence that Epitalon lengthens telomeres, improves healthspan, or extends lifespan in people — and, because telomerase reactivation is also a hallmark of many cancers, the same mechanism carries an oncological question that any translational programme would have to answer.

The Human Record: Epithalamin, Not Epitalon

The most striking human claims attached to this compound family actually come from the parent extract. An Alzheimer's Drug Discovery Foundation review summarises the key trials: a placebo-controlled study treated roughly 70 older adults with "accelerated aging" using intramuscular Epithalamin every six months for three years and followed them for a further nine years, reporting a lower mortality rate and reduced cardiovascular-mortality rate over the twelve-year window; a larger cohort reportedly showed normalised circadian melatonin and metabolic measures.^[4]

Those numbers sound impressive, and that is exactly why the provenance caveat is load-bearing. The same review states directly that every preclinical and clinical study in this literature was conducted by Khavinson's group, with no independent confirmation, and that roughly half of the ~110 published articles are in Russian and unavailable in English translation. It also flags that most human trials used Epithalamin (the extract), not the pure Epitalon tetrapeptide.^[4]

For a research reader, the correct posture is neither dismissal nor endorsement: the signals are real enough to justify independent study, and thin enough that no human efficacy claim should be made until an independent group reproduces them.

Epitalon vs Semax vs MOTS-c — Different Lanes

Researchers often group Epitalon with the other "Russian-heritage" or geroprotective research peptides. The honest answer is that the commonly compared compounds belong to different families and were investigated in different model systems. The table below summarises that, without claiming clinical interchangeability.

None of these molecules is an approved therapeutic, and none has a peptide-specific late-stage human-trial program of the kind seen with incretin agents. For research framing, the cleanest position is to keep Epitalon in the pineal-geroprotection / telomere-biology lane, with Semax in the neuroprotection/nootropic lane and MOTS-c in the mitochondrial-metabolism lane. They are not substitutes for each other in a research-design sense.

What the Epitalon Literature Does Not Yet Give You

Cautious reading of Epitalon requires acknowledging four real gaps:

• No independent human trial. The human data are single-group, largely on the extract, and unreplicated. Anyone framing Epitalon as a proven anti-aging therapeutic is going well beyond the published record.^[4]
• Telomere-to-lifespan leap is unsupported. In-vitro telomerase induction does not establish telomere lengthening, healthspan, or lifespan benefit in humans, and telomerase reactivation raises a separate oncology question that has not been resolved for this peptide.^[2][3]
• Thin physico-chemical characterisation. The 2025 review notes that structural and physico-chemical study of the peptide is limited relative to the volume of biological claims — a gap that matters for reproducibility.^[1]
• Dose translation is unsupported. Published animal and extract doses do not map cleanly to a human dose, and this article makes no attempt to do so. Anyone offering specific "Epitalon protocols" for humans is going outside the published data.

These gaps are not arguments against studying Epitalon. They are arguments against overselling it.

Where Epitalon Fits in a Modern RUO Research Catalog

For research use, Epitalon belongs in the category of pineal / geroprotective peptide research tools — typically supplied as a 10mg lyophilized research vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work, and published against a >99% HPLC line standard. That format is consistent with how investigators have used the peptide in cell-culture and animal-model work in the published literature.

It is not framed for human use, not framed for veterinary use, and not framed as a treatment. The wider compound comparison sits in the research library, and published Janoshik reports for the Retatrutide range sit in the COA library.

For researchers reading this page as a starting point, the most useful adjacent references on this site are the peptide primer, the bacteriostatic water guide, the stability and storage guide, and the peptide legality brief. Researchers comparing Epitalon to other neuro/geroprotective peptides may also want the Semax research review.

FDA PCAC votes July 23–24, 2026: six peptides recommended

The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).

The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.